Evidence map›Paper›PMID 38126028›Full record

ArticleOncoimmunology2023

Whole stromal fibroblast signature is linked to specific chemokine and immune infiltration patterns and to improved survival in NSCLC.

Stefan Koeck, Arno Amann, Johan Kern, Marit Zwierzina, Edith Lorenz, Sieghart Sopper, Heinz Zwierzina, Finn Mildner, Martina Sykora, Susanne Sprung and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Stefan KoeckDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Arno AmannDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Johan KernDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Marit ZwierzinaDepartment of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Edith LorenzDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Sieghart SopperDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Heinz ZwierzinaDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Finn MildnerDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Martina SykoraDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Susanne SprungDepartment of Pathology, Neuropathology, and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Hubert HacklInstitute of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Florian AugustinDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Hubert T MaierDepartment of Visceral, Transplant and Thoracic Surgery, Center of Operative Medicine, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Andreas PircherDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Georg PallDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Dominik WolfDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Gabriele GamerithDepartment of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Tyrol, Austria.
Universität Innsbruck · ATInnsbruck Medical University · ATTyrolean Cancer Research Institute · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer associated fibroblasts (CAF) are known to orchestrate multiple components of the tumor microenvironment, whereas the influence of the whole stromal-fibroblast compartment is less understood. Here, an extended stromal fibroblast signature was investigated to define its impact on immune cell infiltration. The lung cancer adenocarcinoma (LUAD) data set of the cancer genome atlas (TCGA) was used to test whole stroma signatures and cancer-associated fibroblast signatures for their impact on prognosis. 3D cell cultures of the NSCLC cancer cell line A549 together with the fibroblast cell line SV80 were used in combination with infiltrating peripheral blood mononuclear cells (PBMC) for in-vitro investigations. Immune cell infiltration was assessed

Indexed as

Adenocarcinoma of LungCarcinoma, Non-Small-Cell LungLung NeoplasmsChemokinesFibroblastsHumansLeukocytes, MononuclearTumor MicroenvironmentChemokinesCAFcancerco-cultureimmune cellsinfiltrationmicroenvironment

Identifiers

PMID38126028
PMCPMC10732611
OpenAlexW4389150821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.